Document:

EX-10.8

 Exhibit 10.8 

ONCOMED PHARMACEUTICALS, INC. 

NON-EMPLOYEE DIRECTOR COMPENSATION POLICY 

Approved by the Board of Directors on August 28, 2013, as amended October 14, 2013 

Non-employee members of the board of directors (the “Board”) of OncoMed Pharmaceuticals, Inc. (the
“Company”) shall be eligible to receive cash and equity compensation commencing on the date immediately preceding the first date upon which the Company is subject to the reporting requirements of Section 13 or 15(d)(2)
of the Securities Exchange Act of 1934, as amended (the “Public Trading Date”), as set forth in this Non-Employee Director Compensation Policy (this “Policy”). The cash and equity compensation
described in this Policy shall be paid or be made, as applicable, automatically and without further action of the Board, to each member of the Board who is not an employee of the Company or any parent or subsidiary of the Company (each, a
“Non-Employee Director”) who may be eligible to receive such cash or equity compensation, unless such Non-Employee Director declines the receipt of such cash or equity compensation by written notice to the Company. This
Policy shall remain in effect until it is revised or rescinded by further action of the Board. The terms and conditions of this Policy shall supersede any prior cash or equity compensation arrangements between the Company and its Non-Employee
Directors. 
 1. Cash Compensation. 

(a) Annual Retainers. Each Non-Employee Director shall be eligible to receive an annual retainer of $35,000 for service on the Board.
In addition, a Non-Employee Director shall receive the following additional annual retainers, as applicable: 
 (i) Chairperson of the
Audit Committee. A Non-Employee Director serving as Chairperson of the Audit Committee shall receive an additional annual retainer of $15,000 for such service. 

(ii) Member of the Audit Committee. A Non-Employee Director serving as a member of the Audit Committee (other than the Chairperson)
shall receive an additional annual retainer of $10,000 for such service. 
 (iii) Chairperson of the Compensation Committee. A
Non-Employee Director serving as Chairperson of the Compensation Committee shall receive an additional annual retainer of $10,000 for such service. 

(iv) Member of the Compensation Committee. A Non-Employee Director serving as a member of the Compensation Committee (other than the
Chairperson) shall receive an additional annual retainer of $7,000 for such service. 
 (v) Chairperson of the Nominating and Corporate
Governance Committee. A Non-Employee Director serving as Chairperson of the Nominating and Corporate Governance Committee shall receive an additional annual retainer of $8,000 for such service. 

(vi) Member of the Nominating and Corporate Governance Committee. A Non-Employee Director serving as a member of the Nominating and
Corporate Governance Committee (other than the Chairperson) shall receive an additional annual retainer of $5,000 for such service. 

 (b) Payment of Retainers. The annual retainers described in Section 1(a) shall be
earned on a quarterly basis based on a calendar quarter and shall be paid by the Company in arrears. In the event a Non-Employee Director does not serve as a Non-Employee Director, or in the applicable positions described in Section 1(a), for
an entire calendar quarter, the retainer paid to such Non-Employee Director shall be prorated for the portion of such calendar quarter actually served as a Non-Employee Director, or in such positions, as applicable. 

2. Equity Compensation. Non-Employee Directors shall be granted the equity awards described below. The awards described below shall be
granted under and shall be subject to the terms and provisions of the Company’s 2013 Equity Incentive Award Plan (the “Equity Plan”) and shall be granted subject to the execution and delivery of award agreements,
including attached exhibits, in substantially the same forms previously approved by the Board, setting forth the vesting schedule applicable to such awards and such other terms as may be required by the Equity Plan. 

(a) Initial Awards. A person who is initially elected or appointed to the Board following the Public Trading Date, and who is a
Non-Employee Director at the time of such initial election or appointment, shall be eligible to receive a stock option to purchase that number of shares of common stock equal to 0.1% of the Company’s outstanding capital stock on the date of
such initial election or appointment. The awards described in this Section 2(a) shall be referred to as “Initial Awards.” No Non-Employee Director shall be granted more than one Initial Award. 

(b) Subsequent Awards. A person who is a Non-Employee Director immediately following each annual meeting of the Company’s
stockholders after the Public Trading Date and who will continue to serve as a Non-Employee Director immediately following such annual meeting shall be automatically granted an option to purchase 15,000 shares of the Company’s common stock on
the date of each such annual meeting. The awards described in this Section 2(b) shall be referred to as “Subsequent Awards.” For the avoidance of doubt, a Non-Employee Director elected for the first time to the Board at
an annual meeting of the Company’s stockholders shall only receive an Initial Award in connection with such election, and shall not receive any Subsequent Award on the date of such meeting as well. 

(c) Termination of Employment of Employee Directors. Members of the Board who are employees of the Company or any parent or subsidiary
of the Company who subsequently terminate their employment with the Company and any parent or subsidiary of the Company and remain on the Board will not receive an Initial Award pursuant to Section 2(a) above, but to the extent that they are
otherwise eligible, will be eligible to receive, after termination from employment with the Company and any parent or subsidiary of the Company, Subsequent Awards as described in Section 2(b) above. 

(d) Terms of Awards Granted to Non-Employee Directors. 

(i) Purchase Price. The per share exercise price of each option granted to a Non-Employee Director shall equal 100% of the Fair Market
Value (as defined in the Equity Plan) of a share of common stock on the date the option is granted. 
 (ii) Vesting. Each Initial
Award shall vest and become exercisable in three equal annual installments over the three year period following the date of grant, subject to the Non-Employee Director continuing in service on the Board through each such vesting date. Each
Subsequent Award shall vest and/or become exercisable in full upon the earlier of the first anniversary of the date of grant or the date of the next annual meeting of stockholders, subject to the Non-Employee Director continuing in service on the
Board through such vesting date. 

 (iii) Term. The term of each stock option granted to a Non-Employee Director shall be ten
years from the date the option is granted. 
 (iv) Upon a Change in Control (as defined in the Equity Plan) of the Company, all outstanding
equity awards granted under the Equity Plan or any other equity incentive plan maintained by the Company that are held by a Non-Employee Director shall become fully vested and/or exercisable, irrespective of any other provisions of the Non-Employee
Director’s award agreement.EX-10.9

 Exhibit 10.9 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
 AMENDMENT 2 TO THE 

COLLABORATION AND OPTION AGREEMENT 

THIS AMENDMENT 2 TO THE COLLABORATION AND
OPTION AGREEMENT (the “Amendment”) is made and entered into on August 27, 2013 (the “Amendment Date”), by and between OncoMed Pharmaceuticals, Inc. a
Delaware corporation located at 800 Chesapeake Drive. Redwood City, California 94063. United States of America (“OncoMed”), and Bayer Pharma AG, a German corporation located at Müllerstrasse 178, 13353 Berlin, Germany
which previously acted under the name Bayer Schering Pharma AG (“BSP”). OncoMed and BSP are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 

RECITALS 

WHEREAS, OncoMed and BSP entered into a Collaboration and Option Agreement effective as of June 15,
2010 and amended as of August 1, 2012 (as amended, the “Agreement”) pursuant to which they agreed to collaborate to discover and develop biologic and small molecule compounds directed to targets within the Wnt cellular
pathway; 
 WHEREAS, pursuant to Section 6.3.1 and Exhibit 6.3.1 of the Agreement, a
milestone payment is due to OncoMed upon achievement of both the completion of dose escalation in the first Phase I Trial for the 18R5 Collaboration Compound and the Parties’ agreement on the design of a Phase I Trial extension cohort for the
18R5 Collaboration Compound (the “Milestone Payment”); 
 WHEREAS, the Parties
originally jointly agreed on the design of a dose escalation study in a first Phase I Trial of the 18R5 Collaboration Compound (the “First Escalation Study”), in which subjects would receive varying doses of the 18R5 Collaboration
Compound up to a specified maximum dose (the “Original Maximum Dose”); 
 WHEREAS, the Parties
have jointly agreed on the design of the Phase Ib Trials of the 18R5 Collaboration Compound; 

WHEREAS, the Parties have agreed to initiate [***] while continuing [***] to explore further [***]; 

WHEREAS, OncoMed is not obligated under the Agreement to [***], but OncoMed is willing to do so as
long as it is paid the Milestone Payment upon completion of dosing of subjects in the First Escalation Study up to, and including, the Original Maximum Dose and the Parties’ agreement on the design of the Phase Ib Trials; 

WHEREAS, the Parties therefore desire to modify the timing of certain payment terms under the
Agreement relating to the 18R5 Class; and 
 WHEREAS, the Parties desire to clarify BSP’s
right to conduct development and commercialization of [***]. 

 AMENDMENT 

NOW, THEREFORE, in consideration of the foregoing and the mutual agreements set forth below, the Parties
agree as follows: 
 1. Any capitalized terms used in this Amendment shall have the meaning set forth in the Agreement, unless otherwise defined herein.

 2. The Milestone Payment, in the amount of USD 10 million as set forth in Exhibit 6.3.1, shall be payable with respect to the 18R5 Collaboration
Compound pursuant to Section 6.3.1 upon achievement of (i) completion of dosing in the First Escalation Study up to, and including, the Original Maximum Dose, and (ii) the Parties’ agreement on the design of the Phase Ib Trials;

 3. [***]. 
 4. [***] shall be deleted from Exhibit 1.114
and Exhibit 1.114 shall be replaced by the restated version attached to this Amendment. For clarity. BSP shall not use any Assay Technology or OncoMed Intellectual Property in connection with the research, development, manufacturing or
commercialization of any products directed against [***], or any products useful as biomarkers or assays to detect [***] expression or activity, alone or in connection with [***]-targeted therapies. 

 

	5.	All other terms and conditions of the Agreement shall remain in full force and effect. 

 6. This Amendment
maybe executed in counter-parts with the same effect as if both Parties had signed the same document. All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument. Signatures to this
Amendment transmitted by facsimile, by email in “portable document format” (“.pdf”), or by any other electronic means intended to preserve the original graphic and pictorial appearance of this Amendment shall have the same effect
as physical delivery of the paper document bearing original signature. 
 7. This Amendment, together with all Exhibits hereto and the Agreement and all
Exhibits thereto, constitutes the entire agreement between the Parties as to the subject matter of this Amendment, and supersedes and merges all prior and contemporaneous negotiations, representations, agreements and understandings regarding the
same. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their respective duly authorized
officers as of the Effective Date. 
  

									
	ONCOMED PHARMACEUTICALS, INC.	 		 	BAYER PHARMA AG
					
	By:	 	 /s/ Paul J. Hastings
	 		 	By: ppa.	 	   /s/ Andreas Busch

	Name: Paul J. Hastings	 		 	Name: Prof. Dr. Andreas Busch
	Title: President and CEO	 		 	Title: Head of Global Drug Discovery
					
		 		 		 	By: i.V.	 	   /s/ Bertolt Kreft

		 		 		 	Name: Dr. Bertolt Kreft
		 		 		 	Title: Immunotherapy & Anti-body-Drug Conjugates

 Exhibit 1.114 

Pathway 
 [***] the Wnt pathway: 

1. [***] 
 2. [***] 

3. [***] 
 4. [***] 

5. [***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]